Safety of high-dose liposomal daunorubicin (daunoxome) for refractory or relapsed acute myeloblastic leukaemia.
Fassas
Athanasios
A
Buffels
Regine
R
Kaloyannidis
Panayotis
P
Anagnostopoulos
Achilles
A
D000293:Adolescent; D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D003630:Daunorubicin / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008081:Liposomes; D008875:Middle Aged; D016277:Ventricular Function, Left / Q000187:drug effects
D000903:Antibiotics, Antineoplastic; D008081:Liposomes; D003630:Daunorubicin